Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 04/16/24
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewsWire • 03/19/24
Connect Biopharma Appoints Industry Veteran James Huang to Board of DirectorsGlobeNewsWire • 02/12/24
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent AsthmaGlobeNewsWire • 12/12/23
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023GlobeNewsWire • 12/11/23
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 11/28/23
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater ChinaGlobeNewsWire • 11/21/23
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic DermatitisGlobeNewsWire • 11/21/23
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023GlobeNewsWire • 11/20/23
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 11/06/23
Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 10/20/23
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 09/15/23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 09/12/23
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewsWire • 09/12/23
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of DermatologyGlobeNewsWire • 07/10/23
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative ColitisGlobeNewsWire • 06/01/23
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 04/11/23
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient SymptomsBusiness Wire • 03/18/23
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body RegionsBusiness Wire • 03/17/23
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual MeetingBusiness Wire • 03/06/23
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom CaliforniaGlobeNewsWire • 02/06/23